SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is driving intense community activity and speculative buying as traders anticipate a potential breakout and further price discovery. While some market participants express caution regarding volatility and project longevity, the active community remains focused on momentum and the potential for the stock to surpass previous highs.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate the company's massive cash hoard and its continued underperformance relative to broader market benchmarks. Community sentiment remains deeply divided, with some critics slamming management's lack of aggressive capital deployment into AI, while long-term supporters argue that the firm's defensive posture and pending leadership transition under Greg Abel offer stable value in a volatile market.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending on the back of a major $2.8 billion acquisition of the Serra Verde Group, a move widely discussed by the community as a strategic step toward building an end-to-end U.S. supply chain for critical magnets. Investors are closely monitoring the resulting volatility and share dilution implications, while technical analysts debate the sustainability of the recent breakout as interest in rare earth stocks remains heightened by ongoing geopolitical supply concerns.

ProShares Trust - ProShares Ultra Semiconductors 2X Shares

ProShares Ultra Semiconductors

The ProShares Ultra Semiconductors ETF ($USD) is capturing significant investor attention as momentum in the semiconductor sector remains robust, with traders actively debating whether to scale into the fund to capitalize on the continued growth of high-performance AI hardware. Community sentiment is currently driven by the fund's leveraged exposure to industry leaders, leading to intense discussions regarding technical entry points, re-accumulation strategies during market volatility, and the fund's historical performance relative to broader technology-linked ETFs.

Bitcoin Depot, Inc. engages in converting cash into crypto currency. It offers payments, spending, and investing space through its kiosks and BDCheckout product. The company was founded by Brandon Mintz in July 2016 and is headquartered in Sandy Springs, GA.

Bitcoin Depot Inc - Ordinary Shares - Class A

Bitcoin Depot Inc

Bitcoin Depot is trending as investors react to a significant quarterly profit surge and expanded kiosk partnerships, even as the stock deals with volatility from a recent share offering. The community is actively debating the stock's valuation versus its growth prospects, with many focused on whether current price levels present a long-term entry point for a sector leader that is actually profitable.

Polygon

Polygon is capturing attention as community members debate its potential for a turnaround, driven by active network usage in stablecoin payments and discussions around institutional adoption. Investors remain divided, balancing excitement over network activity and ecosystem developments against frustrations regarding recent price performance and circulating supply concerns.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors debate its long-term industrial value against ongoing volatility, fueled by active community discussion regarding a potential strategic partnership with POSCO and the company's role in the domestic infrastructure supply chain. Traders are closely monitoring the stock's technical support levels and high short interest, weighing the impact of fluctuating commodity prices and sector-specific catalysts against concerns over the company's debt profile and leadership.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is trending as investors weigh potential bullish catalysts, including record transaction volume and aggressive share buybacks, against broader concerns over corporate governance and macroeconomic volatility. The community is actively debating the company's long-term profitability and valuation compared to BNPL competitors ahead of upcoming quarterly earnings.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to anticipation surrounding upcoming token burn mechanisms and potential legal developments, with the community actively discussing prospects for supply reduction and long-term price recovery. Enthusiastic participants are highlighting technical chart patterns and volume spikes, while debates continue among those viewing the project as a high-risk contrarian play versus those focused on its historical ecosystem utility.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heavy social media volume as the community debates its long-term potential following recent quantum-security research and institutional accumulation. While some traders discuss the possibility of a price squeeze, others remain skeptical, focusing on the asset's historical price action and ongoing concerns about regulatory adoption.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics Faces Timeline Risk But Upside Could Be Huge

Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside...

Viking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent disclosure...

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.

<ul class="summary-bullets"><li>Big Tech earnings delivered mixed signals, with rising AI capex plans raising concerns about near-term profitability.</li><li>Oil surged amid escalating tensions with Iran, the United States Oil Fund ETF (USO) has surged 128% this year.&nbsp;</li><li>Investors now turn to PCE inflation data and jobless claims for clues on the Fed’s next move.</li></ul>U.S. stock futures slipped in early trade on Thursday as investors digested the wave of Big Tech earnings and rising geopolitical tensions in the Middle East.&nbsp;Brent crude futures jumped nearly 7% to over $120 following reports that President Trump is reviewing military strike options against Iran to break a nuclear negotiation deadlock. Shares of the United States Oil Fund ETF (USO) have risen over 120% this year so far.&nbsp;As of 4:00 a.m. ET on Thursday: Dow futures were down 0.6%, Russell 2000 futures declined 0.3%, S&amp;P 500 futures were down 0.1%, while Nasdaq futures were flat with a positive bias.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has remained in ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has moved back to ‘bullish’ from ‘neutral’ a day ago, even as four of the largest tech firms are now projecting combined capex of up to $725 billion by 2026.Trending Stocks To WatchMeta (META)&nbsp;stock fell another 9% in early premarket trade on bloated 2026 capex forecast of up to $145 billion and missed user growth. The Zuckerberg-led company signaled that its massive AI investments may take years to yield a significant return.&nbsp;Intel Corp (INTC): Shares continued their upmove from last week’s blowout beat, with fresh boost coming from U.S. President Donald Trump. In addition, news reports suggest it is in conversation with custom chip talks with Apple and Google.&nbsp;Microsoft (MSFT) posted a solid cloud beat, which was offset by a Q4 revenue outlook that missed analyst estimates. Stock fell nearly 2% in early premarket trading on Thursday.Alphabet Inc (GOOGL):&nbsp;Stock rose 6% in early premarket trade, rallying on cloud strength and continued AI momentum.&nbsp;Amazon (AMZN): Stock rose 3% in early premarket trade following a first-quarter beat.Qualcomm (QCOM)&nbsp;shares surged nearly 13% in early premarket trade after announcing in its earnings call that it will soon ship data center chips to a major hyperscale cloud provider.&nbsp;Apple (AAPL)&nbsp;will report its second quarter earnings on Thursday after the bell, its first report since it announced that John Ternus will succeed Tim Cook as CEO.&nbsp;Nvidia (NVDA):&nbsp;Reports suggest that black-market crackdowns in China have doubled the price of B300 AI servers to $1 million each.&nbsp;Shares of&nbsp;Viking Therapeutics, Inc. (VKTX)&nbsp;were under mild pressure in premarket trading on Thursday after the drugmaker said that its newer obesity drug candidate beat Novo Nordisk’s comparable therapy in animal studies.Robinhood (HOOD): Stock took a knock on Wednesday after missing Q1 revenue and EPS estimates.&nbsp;In an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/robinhood-cfo-addresses-hood-stock-selloff-after-q1-earnings-miss/cZBAOTvReEi">exclusive interview</a> with Stocktwits, Robinhood CFO Shiv Verma said the earnings miss was driven by a surge in active traders on lower pricing tiers, not weak demand. He added that April is tracking equity and options volumes at the highest month of the year, and on pace to be the second-best month in company history.&nbsp;Intellia Therapeutics (NTLA): Cathie Wood’s ARK Invest added more shares on Wednesday, along with HOOD.Other tickers trending on Stocktwits&nbsp;at the time of writing included Akanda Corp (AKAN), Jaguar Health Inc (JAGX) and Rolls Royce (RYCEY).Other Catalysts To WatchOn the economic front, traders will be watching the release of the PCE Price Index, a critical inflation gauge, alongside Initial Jobless Claims and the Chicago PMI.&nbsp;On earnings radar, watch out for quarterly reports from Caterpillar Inc (CAT), Eli Lilly (LLY), Mastercard Inc Class A (MA), Royal Caribbean Group Ltd (RCL), and Merck &amp; Co (MRK), among others, before the bell. Apart from Appls, Riot Platforms (RIOT), iBio Inc (IBIO), Rivian Automotive (RIVN), and others, report after-market close today.Editors Note: This copy has been updated to correct an earlier error in which the Amazon CEO was incorrectly referenced under the Alphabet (Google) section. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Lower As Trump Reviews Iran Strike Option: Why META, INTC, GOOGL, AAPL, QCOM, VKTX Are Keeping Traders Engaged Today

Data from Stocktwits shows that despite volatility, retail traders stayed bullish on SPY and turned positive again on QQQ.

Nasdaq, S&P 500 Futures Slip Ahead Of PCE Data, Oil Jumps On Iran Strike Fears: Why META, INTC, GOOGL, AAPL, QCOM, VKTX Are In Focus

Equity

Data from Stocktwits shows that despite volatility, retail traders stayed bullish on SPY and turned positive again on QQQ.


<ul class="summary-bullets"><li>The company's obesity drug candidate VK3019 showed stronger early weight-loss signals than Novo Nordisk’s amylin therapy.</li><li>The company said enrollment has been completed across both Phase 3 Vanquish trials evaluating weekly injectable VK2735.</li><li>Viking plans to launch Phase 3 development of the oral VK2735 formulation in Q4.</li></ul>Shares of Viking Therapeutics, Inc. (VKTX) slipped 0.4% in premarket trading on Thursday even after the drugmaker said that its newer obesity drug candidate delivered stronger early weight-loss signals than Novo Nordisk’s comparable therapy in animal studies.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is on track to post its second straight month of losses, sliding nearly 4% so far in April.&nbsp;<h2 class="st-heading-2">VK3019 Boosts Viking’s Challenge To Novo Nordisk&nbsp;</h2>Investor sentiment has largely turned on optimism toward VK3019, Viking’s obesity candidate targeting the amylin receptor, a mechanism increasingly viewed as complementary to GLP-1-based therapies.CEO Brian Lian said on the company’s recent earnings call that early testing suggested the compound compared favorably with Novo Nordisk’s amylin candidate: “When we looked at data in rodents, it seemed to be better than Cagrilintide.”He also noted stronger signals relative to Viking’s own lead obesity therapy in animal testing, saying, “When we looked in obese monkeys, it seemed to provide better weight loss than VK2735.”“it was very potent on the receptors, very good PK [pharmacokinetics] profile that would be amenable to weekly dosing, we think, and that marries up nicely with the 2735-PK profile.” The company recently filed an investigational new drug application for VK3019 and expects to begin Phase 1 testing this quarter.<h2 class="st-heading-2">Viking Eyes Combo Obesity Strategy</h2>Viking also confirmed early discussions around combination development linking VK3019 with VK2735, pointing to a broader multi-mechanism obesity platform strategy. Lian said that the amylin program may expand treatment flexibility for patients unable to tolerate GLP-1 therapies.“Nice opportunity with this mechanism to potentially target people who are a little lower BMI… or people who maybe can’t tolerate the GLP-1 and want to try something different,” Lian added.<h2 class="st-heading-2">Phase 3 Momentum Builds For Lead Candidate&nbsp;</h2>While VK3019 drew attention for its early signals, Viking’s primary focus still remains VK2735, its dual GLP-1 and GIP receptor agonist being developed in both injectable and oral forms. The company said that enrollment has now been completed across both Phase 3 Vanquish trials evaluating weekly injectable VK2735 in adults with obesity and those with obesity plus type 2 diabetes.Alongside the injectable program, Viking is preparing to advance its oral VK2735 tablet formulation into Phase 3 development later this year following encouraging mid-stage trial results. The company said, “Every patient’s weight loss journey is unique, and we consistently hear from health care providers about the need for flexible treatment and administration options.”The company expects to initiate the Phase 3 oral program in the fourth quarter.<h2 class="st-heading-2">VKTX Q1 Review</h2>Viking reported a first-quarter net loss of $158.3 million, or $1.37 per share, wider than the consensus estimate of a $0.91 per-share loss and more than triple the $45.6 million, or $0.41 per share, loss recorded a year ago.&nbsp;The increase was largely driven by a sharp rise in research and development spending to advance its Phase 3 obesity trials and manufacturing activities. Research and development expenses rose to $150 million during the quarter from $41 million a year earlier.Despite the higher spending levels, the company ended the quarter with approximately $603 million in cash, cash equivalents and short-term investments, compared with $706 million at the end of 2025.<h2 class="st-heading-2">How Do Retail Traders View VKTX?</h2>On Stocktwits, retail sentiment for VKTX jumped to ‘bullish’ from ‘bearish’ levels a day ago amid nearly a 200% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_a09757779d.webp" alt="vktx ss.png" width="975" height="148"><figcaption>VKTX sentiment and message volume as of April 30 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/symbol/VKTX">said</a>, “Viking therapeutics is synonymous with the word goldmine. I can't wait to see this cross the finish line. It's going to be a glorious day!”<stembedurl>https://stocktwits.com/symbol/VKTX</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/crypto_biotech/message/651823565">said</a> VKTX was “BASICALLY Best in Class in everything.”<stembedurl>https://stocktwits.com/crypto_biotech/message/651823565</stembedurl>VKTX stock has risen 12% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uso-etf-surges-trump-iran-conflict-us-oil-supplier-last-resort/cZBMGwGReEz">USO ETF Eyes Record Year As Trump Weighs Iran Escalation — US Seen As Oil Market’s ‘Supplier Of Last Resort’&nbsp;</a>

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Slips Premarket: A Surprise Weight Loss Drug Beats Novo Nordisk In Early Animal Tests 

Viking confirmed early combination-development discussions between VK3019 and VK2735.

A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival

Viking Therapeutics Q1 Earnings Call Highlights

Viking Therapeutics (NASDAQ:VKTX) reported first-quarter 2026 financial results and outlined progress across its obesity pipeline during an earnings call held April 29, 2026. Management emphasized...

<ul class="summary-bullets"><li>The company posted a Q1 net loss of $158.3 million, or $1.37 per share — more than triple the $45.6 million loss reported in the year-ago period.</li><li>Viking ended the quarter with $603 million in cash, cash equivalents, and short-term investments, down from $706 million at year-end 2025.</li><li>The company also confirmed plans to launch a late-stage trial of the oral tablet formulation of VK2735 in the fourth quarter of 2026.</li></ul> Shares of Viking Therapeutics (VKTX) dropped 2% after hours on Wednesday after the clinical-stage biotech reported first-quarter results that showed a sharp increase in cash burn tied to the rapid advancement of its late-stage obesity and metabolic disease pipeline.The company posted a net loss of $158.3 million, or $1.37 per share, for the quarter ended March 31, 2026 — more than triple the $45.6 million loss ($0.41 per share) reported in the year-ago period. Research and development expenses jumped to $150.2 million from $41.4 million a year earlier, driven by clinical trial costs, manufacturing scale-up, and personnel expenses related to its lead programs.Viking ended the quarter with $603 million in cash, cash equivalents, and short-term investments, down from $706 million at year-end 2025 but still providing a substantial runway for its clinical programs.<h2 class="st-heading-2">Viking’s Pipeline Efforts</h2>Viking is currently trying to advance its flagship obesity candidate VK2735, a dual GLP-1/GIP receptor agonist available in both subcutaneous and oral formulations. Both late-stage trials of the subcutaneous version are now fully enrolled ahead of schedule. While one of the studies enrolled more than 4,500 patients, the other enrolled approximately 1,000 patients.The company also confirmed plans to launch a late-stage trial of the oral tablet formulation of VK2735 in the fourth quarter of 2026, following positive feedback from an end-of-Phase 2 meeting with the FDA.An ongoing Phase 1 maintenance dosing study for VK2735 — evaluating various regimens after initial weight loss — completed enrollment in January, with data expected in the third quarter of 2026.On the earlier-stage front, Viking filed an application seeking to commence clinical trials for its novel amylin agonist VK3019 in the first quarter. Viking expects to initiate an early-stage trial in the second quarter of 2026. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic cells to manage glucose levels and appetite. The candidate is being developed as a potential option for patients who may not tolerate GLP-1-based therapies.Viking CEO Brian Lian said in March that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.<h2 class="st-heading-2">How Did VKTX Retail Traders React?</h2>On Stocktwits, retail sentiment around VKTX jumped from 'bearish' to 'bullish' territory over the past 24 hours, while message volume increased from 'low' to 'normal' levels.A Stocktwits user expressed optimism for the company’s obesity pipeline.<stembedurl>https://www.stocktwits.com/Robbullishious/message/651824368</stembedurl>Another highlighted the size of the obesity market, while drawing a parallel between VKTX’s lead candidate and Eli Lilly’s development pipeline.<stembedurl>https://www.stocktwits.com/durocali/message/651823807</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX</a> has gained 12% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pypl-stock-rises-after-considering-splitting-off-venmo-as-standalone-segment-report/cZBAXVsReES">PYPL Stock Rises After Considering Splitting Off Venmo As Standalone Segment: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

VKTX Shares Drop After Hours On Larger Q1 Losses But Retail Eyes The Launch Of Its Obesity Pipeline

Viking is currently trying to advance its flagship obesity candidate VK2735, available in both subcutaneous and oral formulations.

Viking Therapeutics (NASDAQ:VKTX) Releases Earnings Results, Misses Estimates By $0.36 EPS

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the...

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...

Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?

Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.24	--	--	N/A
Q1 '26	-$0.98	-$1.37	-40.43%	MISSED
Q4 '25	-$0.90	-$1.38	-53.80%	MISSED
Q3 '25	-$0.70	-$0.81	-15.17%	MISSED
Q2 '25	-$0.45	-$0.58	-29.90%	MISSED

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest VKTX News

VKTXViking Therapeutics Inc